Healthcare stocks
987 US Healthcare companies with filed annual reports. The largest 50 are below with the ratios the screener prints; every company is one link away, by industry or by name.
Industries
- Biotechnology (549)
- Drug Manufacturers - General (20)
- Drug Manufacturers - Specialty & Generic (68)
- Medical - Care Facilities (40)
- Medical - Devices (116)
- Medical - Diagnostics & Research (51)
- Medical - Distribution (8)
- Medical - Equipment & Services (6)
- Medical - Healthcare Information Services (41)
- Medical - Healthcare Plans (11)
- Medical - Instruments & Supplies (50)
- Medical - Pharmaceuticals (14)
- Pharmaceutical Preparations (6)
- Surgical & Medical Instruments & Apparatus (3)
Also in this sector, too small for a page of their own: Medical - Specialties (1), Medicinal Chemicals & Botanical Products (2), Services-Offices & Clinics of Doctors of Medicine (1).
Medians across Healthcare companies
- Price to earnings
- 25.66x of 213
- Price to book
- 2.70x of 687
- Enterprise value to EBIT
- 22.87x of 157
- Free cash flow yield
- -3.6% of 626
- Return on invested capital, after tax
- 5.0% of 221
- Debt to equity
- 0.30 of 441
- Dividend yield
- 0.9% of 76
The largest 50
| Company | Market cap | P/E | P/B | EV/EBIT | FCF yld | ROIC | D/E | Div yld |
|---|---|---|---|---|---|---|---|---|
| Eli Lilly and Company LLY | 1.18T | 54.42x | 42.42x | 43.65x | 0.8% | 33.8% | 1.65 | 0.5% |
| Johnson & Johnson JNJ | 610.40B | 22.76x | 7.55x | 19.22x | 3.2% | 24.8% | 0.61 | 2.1% |
| AbbVie Inc. ABBV | 500.80B | 119.57x | n/m | 37.52x | 3.5% | 16.1% | n/m | 2.4% |
| UnitedHealth Group Incorporated UNH | 365.00B | 30.62x | 3.94x | 22.63x | 4.3% | 10.8% | 0.88 | 2.2% |
| Merck & Co., Inc. MRK | 358.60B | 19.91x | 6.93x | 17.85x | 3.4% | 21.9% | 0.96 | 2.3% |
| Novartis AG NVS | 285.80B | 20.44x | 6.20x | 17.29x | 6.2% | 23.1% | 0.66 | n/a |
| AstraZeneca PLC AZN | 258.50B | 25.28x | 5.31x | 20.68x | 4.5% | 15.2% | 0.65 | 1.9% |
| Thermo Fisher Scientific Inc. TMO | 257.50B | 39.19x | 4.93x | 38.02x | 2.4% | 8.5% | 0.77 | 0.3% |
| Amgen Inc. AMGN | 234.70B | 30.29x | 27.17x | 31.01x | 3.4% | 14.2% | 6.40 | 2.3% |
| Gilead Sciences, Inc. GILD | 195.10B | 23.01x | 8.70x | 21.50x | 4.8% | 21.4% | 1.13 | 2.1% |
| Abbott Laboratories ABT | 181.20B | 28.07x | 3.51x | 23.42x | 4.0% | 10.8% | 0.27 | 2.4% |
| Novo Nordisk A/S NVO | 174.40B | 11.35x | 5.99x | n/a | 5.1% | n/a | n/a | 4.5% |
| Pfizer Inc. PFE | 167.80B | 21.49x | 1.94x | 23.01x | 5.4% | n/a | 0.78 | 5.8% |
| Danaher Corporation DHR | 162.70B | 45.66x | 3.16x | 38.56x | 3.2% | 5.9% | 0.37 | 0.7% |
| Intuitive Surgical, Inc. ISRG | 151.20B | 53.48x | 8.71x | n/a | 1.6% | n/a | n/a | n/a |
| Vertex Pharmaceuticals Incorporated VRTX | 128.90B | 32.91x | 7.03x | n/a | 2.4% | n/a | n/a | n/a |
| Bristol-Myers Squibb Company BMY | 123.70B | 17.46x | 6.69x | 14.30x | 10.4% | 15.3% | 2.55 | 4.2% |
| Medtronic plc MDT | 122.10B | 25.45x | 2.49x | 23.23x | 4.4% | 6.6% | 0.59 | 3.0% |
| CVS Health Corporation CVS | 118.40B | 66.13x | 1.56x | 40.88x | 6.6% | 2.5% | 1.08 | 2.9% |
| McKesson Corporation MCK | 116.40B | 25.91x | n/m | 20.73x | 4.6% | 192.3% | n/m | 0.3% |
| Stryker Corporation SYK | 112.50B | 34.54x | 5.06x | 25.71x | 3.8% | 10.1% | 0.73 | 1.2% |
| HCA Healthcare, Inc. HCA | 101.40B | 16.32x | n/m | 13.30x | 6.9% | 22.6% | n/m | 0.7% |
| Sanofi SNY | 98.69B | 11.26x | 1.23x | 15.89x | 8.2% | n/a | 0.29 | n/a |
| GSK plc GSK | 98.21B | 12.95x | 4.52x | n/a | 8.6% | n/a | n/a | n/a |
| Moderna, Inc. MRNA | 94.42B | n/m | 10.64x | n/a | -2.2% | n/a | 0.15 | n/a |
| Elevance Health Inc. ELV | 92.91B | 16.95x | 2.19x | 16.59x | 3.3% | 9.1% | 0.75 | 1.6% |
| Regeneron Pharmaceuticals, Inc. REGN | 81.99B | 18.49x | 2.77x | n/a | 4.7% | n/a | n/a | 0.5% |
| Cigna Corporation CI | 78.96B | 13.38x | 1.92x | 11.32x | n/a | 11.3% | 0.76 | 2.1% |
| Cencora, Inc. COR | 65.15B | 42.57x | 44.20x | 27.25x | 4.8% | 28.1% | 6.19 | 0.7% |
| Boston Scientific Corporation BSX | 63.97B | 22.52x | 2.72x | 21.06x | 5.5% | 9.0% | 0.50 | n/a |
| Takeda Pharmaceutical Company Limited TAK | 61.73B | 90.42x | 1.41x | 42.22x | 8.8% | 1.8% | 0.73 | n/a |
| Cardinal Health, Inc. CAH | 58.75B | 34.90x | n/m | 25.03x | 7.5% | 85.6% | n/m | 0.8% |
| Natera, Inc. NTRA | 58.35B | n/m | 32.32x | n/a | 0.2% | n/a | n/a | n/a |
| argenx SE ARGX | 53.22B | 41.19x | 7.27x | 47.23x | 1.3% | n/a | 0.01 | n/a |
| Becton, Dickinson and Company BDX | 52.78B | 33.23x | 2.20x | 29.22x | 4.8% | 5.1% | 0.79 | 2.0% |
| Humana Inc. HUM | 51.90B | 43.79x | 2.96x | 22.53x | 0.7% | 8.5% | 0.73 | 0.8% |
| Edwards Lifesciences Corporation EW | 50.76B | 47.88x | 4.99x | n/a | 2.6% | n/a | n/a | n/a |
| Veeva Systems Inc. VEEV | 50.68B | 56.40x | 7.25x | 55.60x | n/a | 11.8% | 0.01 | n/a |
| Agilent Technologies, Inc. A | 49.50B | 38.25x | 7.42x | 35.01x | 2.3% | 15.8% | 0.53 | 0.6% |
| Teva Pharmaceutical Industries Limited TEVA | 47.91B | 33.42x | 6.04x | n/a | 2.4% | n/a | n/a | n/a |
| IQVIA Holdings Inc. IQV | 44.61B | 34.27x | 7.23x | 28.10x | 4.4% | 8.8% | 2.50 | n/a |
| Haleon plc HLN | 43.71B | 19.76x | 2.01x | 16.68x | 7.0% | 7.9% | 0.52 | n/a |
| Waters Corporation WAT | 43.61B | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| IDEXX Laboratories, Inc. IDXX | 43.11B | 41.55x | 27.62x | 32.89x | 2.4% | 54.3% | 0.36 | n/a |
| Revolution Medicines, Inc. RVMD | 40.57B | n/m | 22.06x | n/a | -2.5% | n/a | n/a | n/a |
| Illumina, Inc. ILMN | 40.46B | 48.98x | 15.35x | n/a | 2.2% | n/a | n/a | n/a |
| BeOne Medicines Ltd. ONC | 39.97B | n/a | n/a | n/a | n/a | 33.6% | 0.25 | n/a |
| Centene Corporation CNC | 34.83B | n/m | 1.74x | n/a | 12.4% | -37.4% | 0.91 | n/a |
| Biogen Inc. BIIB | 34.77B | 26.65x | 1.90x | 20.98x | 5.9% | 6.9% | 0.36 | n/a |
| ResMed Inc. RMD | 34.07B | 23.14x | 5.37x | 18.41x | 4.7% | 25.2% | 0.13 | 1.0% |
Largest published market value first. No ratio orders this list, and a company whose market value is not published is listed last.
Every other Healthcare company outside an industry page
Prices as of 2026-10-15. Ratios recomputed from the filings 2026-10-15. Every ratio passes the same applicability gate as the screener and the research page, with the latest filed fiscal year's statements. A list is not a recommendation: see the limits of what this tool can tell you.